{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:08:09Z","timestamp":1768709289749,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"DOI":"10.7759\/cureus.101737","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T14:41:43Z","timestamp":1768660903000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Relationship Between Programmed Death Ligand-1 (Clone: 22C3), Anaplastic Lymphoma Kinase (D5F3), and C-ros Oncogene 1 (OT11A1) Expression in Lung Adenocarcinoma"],"prefix":"10.7759","author":[{"given":"Kartavya K","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bugalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajoy K","family":"Behera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nighat","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 5.2018","volume":"16","author":"Ettinger DS","year":"2018","unstructured":"Ettinger DS, Aisner DL, Wood DE, et al.. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018, 16:807-21. 10.6004\/jnccn.2018.0062","journal-title":"J Natl Compr Canc Netw"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMx150034","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"373","year":"2015","unstructured":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2015, 373.1582. 10.1056\/NEJMx150034","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"U. S. Food and Drug Administration. FDA approves crizotinib capsules. (2016). Accessed: January 27, 2021: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-crizotinib-capsules."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-33. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.12.026","article-title":"Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 \u226550% expression in lung adenocarcinoma","volume":"12","author":"Rangachari D","year":"2017","unstructured":"Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 \u226550% expression in lung adenocarcinoma. J Thorac Oncol. 2017, 12:878-83. 10.1016\/j.jtho.2016.12.026","journal-title":"J Thorac Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107788","article-title":"Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression","volume":"191","author":"Miyakoshi J","year":"2024","unstructured":"Miyakoshi J, Yoshida T, Kashima J, et al.. Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression. Lung Cancer. 2024, 191:107788. 10.1016\/j.lungcan.2024.107788","journal-title":"Lung Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman NI","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL, et al.. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018, 142:321-46. 10.5858\/arpa.2017-0388-CP","journal-title":"Arch Pathol Lab Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_333_19","article-title":"Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center","volume":"37","author":"Mohan A","year":"2020","unstructured":"Mohan A, Garg A, Gupta A, et al.. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India. 2020, 37:190-7. 10.4103\/lungindia.lungindia_333_19","journal-title":"Lung India"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3651","article-title":"Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas","volume":"48","author":"Clark VE","year":"2016","unstructured":"Clark VE, Harmanc\u0131 AS, Bai H, et al.. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet. 2016, 48:1253-9. 10.1038\/ng.3651","journal-title":"Nat Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2004.00621.x","article-title":"The accuracy of meningioma grading: a 10-year retrospective audit","volume":"31","author":"Willis J","year":"2005","unstructured":"Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D. The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol. 2005, 31:141-9. 10.1111\/j.1365-2990.2004.00621.x","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark VE","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, et al.. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science. 2013, 339:1077-80. 10.1126\/science.1233009","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4103\/ijpm.ijpm_939_23","article-title":"Association between PD-L1 expression with EGFR , ALK , and ROS1 driver oncogene mutations in non-small cell lung cancer","volume":"68","author":"Onur D","year":"2025","unstructured":"Onur D, \u0130lhan Y, B\u00fcge \u00d6. Association between PD-L1 expression with EGFR , ALK , and ROS1 driver oncogene mutations in non-small cell lung cancer. Indian J Pathol Microbiol. 2025, 68:36-41. 10.4103\/ijpm.ijpm_939_23","journal-title":"Indian J Pathol Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100868","article-title":"The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients","volume":"42","author":"Wang L","year":"2024","unstructured":"Wang L, Kong Y, Zhang Y, Mu C. The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients. Cancer Treat Res Commun. 2024, 42:100868. 10.1016\/j.ctarc.2025.100868","journal-title":"Cancer Treat Res Commun"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.513","article-title":"Concurrent EGFR mutation and ALK translocation in non-small cell lung cancer","volume":"8","author":"Sweis RF","year":"2016","unstructured":"Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR mutation and ALK translocation in non-small cell lung cancer. Cureus. 2016, 8:e513. 10.7759\/cureus.513","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3351","article-title":"Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion","volume":"18","author":"Rimkunas VM","year":"2012","unstructured":"Rimkunas VM, Crosby KE, Li D, et al.. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012, 18:4449-57. 10.1158\/1078-0432.CCR-11-3351","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon K","year":"2012","unstructured":"Bergethon K, Shaw AT, Ou SH, et al.. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012, 30:863-70. 10.1200\/JCO.2011.35.6345","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.900","article-title":"ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes","volume":"13","author":"Joshi A","year":"2019","unstructured":"Joshi A, Pande N, Noronha V, et al.. ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes. Ecancermedicalscience. 2019, 13:900. 10.3332\/ecancer.2019.900","journal-title":"Ecancermedicalscience"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/crst.crst_314_23","article-title":"Molecular analysis for EGFR, ALK, and ROS1 alterations in over 3000 Indian patients with non-small-cell lung cancer: a retrospective observational study","volume":"7","author":"Munde S","year":"2024","unstructured":"Munde S, Barodawala S, Lila K, et al.. Molecular analysis for EGFR, ALK, and ROS1 alterations in over 3000 Indian patients with non-small-cell lung cancer: a retrospective observational study. Cancer Res Stat Treat. 2024, 7:11-8. 10.4103\/crst.crst_314_23","journal-title":"Cancer Res Stat Treat"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.117023","article-title":"Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients","volume":"50","author":"Choughule A","year":"2013","unstructured":"Choughule A, Noronha V, Joshi A, et al.. Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. Indian J Cancer. 2013, 50:107-11. 10.4103\/0019-509X.117023","journal-title":"Indian J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2017.09.005","article-title":"A study of therapy targeted EGFR\/ALK mutations in Indian patients with lung adenocarcinoma: a clinical and epidemiological study","volume":"74","author":"Rana V","year":"2018","unstructured":"Rana V, Ranjan P, Jagani R, Rathi KR, Kumar D, Khera A. A study of therapy targeted EGFR\/ALK mutations in Indian patients with lung adenocarcinoma: a clinical and epidemiological study. Med J Armed Forces India. 2018, 74:148-53. 10.1016\/j.mjafi.2017.09.005","journal-title":"Med J Armed Forces India"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061561","article-title":"EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy","volume":"8","author":"Noronha V","year":"2013","unstructured":"Noronha V, Prabhash K, Thavamani A, et al.. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS One. 2013, 8:e61561. 10.1371\/journal.pone.0061561","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.190356","article-title":"Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: prevalence and relation with different clinical variables","volume":"37","author":"Kasana BA","year":"2016","unstructured":"Kasana BA, Dar WR, Aziz SA, et al.. Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: prevalence and relation with different clinical variables. Indian J Med Paediatr Oncol. 2016, 37:189-95. 10.4103\/0971-5851.190356","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7243\/2049-7962-3-4","article-title":"A study of incidence of EGFR mutations in non-smoker adenocarcinoma of the lung: disparity between North and South Indian patients","volume":"3","author":"Pungliya M","year":"2014","unstructured":"Pungliya M, Sachin M, Soumittra N, Shekar P, Shyam A. A study of incidence of EGFR mutations in non-smoker adenocarcinoma of the lung: disparity between North and South Indian patients. J Cancer Ther Res. 2014, 3:4. 10.7243\/2049-7962-3-4","journal-title":"J Cancer Ther Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1204","article-title":"Epidermal growth factor receptor mutation frequency in squamous cell carcinoma and its diagnostic performance in cytological samples: a molecular and immunohistochemical study","volume":"10","author":"Kumari N","year":"2019","unstructured":"Kumari N, Singh S, Haloi D, Mishra SK, Krishnani N, Nath A, Neyaz Z. Epidermal growth factor receptor mutation frequency in squamous cell carcinoma and its diagnostic performance in cytological samples: a molecular and immunohistochemical study. World J Oncol. 2019, 10:142-50. 10.14740\/wjon1204","journal-title":"World J Oncol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/CRST.CRST_12_19","article-title":"Determination of ROS1 positivity by immunohistochemistry in a multicentric cohort of 426 non-small-cell lung cancer cases in India","volume":"2","author":"Jain J","year":"2019","unstructured":"Jain J, Chinta D, Jayaraman UB, et al.. Determination of ROS1 positivity by immunohistochemistry in a multicentric cohort of 426 non-small-cell lung cancer cases in India. Cancer Res Stat Treat. 2019, 2:16-20. 10.4103\/CRST.CRST_12_19","journal-title":"Cancer Res Stat Treat"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S244366","article-title":"Incidence of ROS1-rearranged non-small-cell lung carcinoma in India and efficacy of crizotinib in lung adenocarcinoma patients","volume":"11","author":"Mehta A","year":"2020","unstructured":"Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K. Incidence of ROS1-rearranged non-small-cell lung carcinoma in India and efficacy of crizotinib in lung adenocarcinoma patients. Lung Cancer (Auckl). 2020, 11:19-25. 10.2147\/LCTT.S244366","journal-title":"Lung Cancer (Auckl)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_488_19","article-title":"Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer","volume":"37","author":"Kumar M","year":"2020","unstructured":"Kumar M, Guleria B, Swamy S, Soni S. Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer. Lung India. 2020, 37:145-50. 10.4103\/lungindia.lungindia_488_19","journal-title":"Lung India"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_116_17","article-title":"ROS1 rearrangement and response to crizotinib in stage IV non-small cell lung cancer","volume":"34","author":"Suryavanshi M","year":"2017","unstructured":"Suryavanshi M, Panigrahi MK, Kumar D, et al.. ROS1 rearrangement and response to crizotinib in stage IV non-small cell lung cancer. Lung India. 2017, 34:411-4. 10.4103\/lungindia.lungindia_116_17","journal-title":"Lung India"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson AG","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB, et al.. The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol. 2022, 17:362-87. 10.1016\/j.jtho.2021.11.003","journal-title":"J Thorac Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182960fa7","article-title":"ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas","volume":"37","author":"Sholl LM","year":"2013","unstructured":"Sholl LM, Sun H, Butaney M, Zhang C, Lee C, J\u00e4nne PA, Rodig SJ. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013, 37:1441-9. 10.1097\/PAS.0b013e3182960fa7","journal-title":"Am J Surg Pathol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.04.017","article-title":"Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type","volume":"63","author":"Ninomiya H","year":"2009","unstructured":"Ninomiya H, Hiramatsu M, Inamura K, et al.. Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer. 2009, 63:235-40. 10.1016\/j.lungcan.2008.04.017","journal-title":"Lung Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182a406d1","article-title":"Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas","volume":"9","author":"Wang R","year":"2014","unstructured":"Wang R, Pan Y, Li C, et al.. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol. 2014, 9:760-8. 10.1097\/JTO.0b013e3182a406d1","journal-title":"J Thorac Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109742","article-title":"Morphological basis of the lung adenocarcinoma subtypes","volume":"27","author":"Zha L","year":"2024","unstructured":"Zha L, Matsu-Ura T, Sluka JP, Murakawa T, Tsuta K. Morphological basis of the lung adenocarcinoma subtypes. iScience. 2024, 27:109742. 10.1016\/j.isci.2024.109742","journal-title":"iScience"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447564-evaluating-the-relationship-between-programmed-death-ligand-1-clone-22c3-anaplastic-lymphoma-kinase-d5f3-and-c-ros-oncogene-1-ot11a1-expression-in-lung-adenocarcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T14:41:48Z","timestamp":1768660908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447564-evaluating-the-relationship-between-programmed-death-ligand-1-clone-22c3-anaplastic-lymphoma-kinase-d5f3-and-c-ros-oncogene-1-ot11a1-expression-in-lung-adenocarcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.101737","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,17]]}}}